**REVIEW ARTICLE**

# Advances in Cancer Therapy: A Comprehensive Review of Fourth Generation EGFR Inhibitors and their Role in Defeating Drug Resistance

Asha Hole*, Shashikant Bhandari

*Department of Pharmaceutical Chemistry, AISSMS's College of Pharmacy, Shivajinagar, Affiliated to Savitribai Phule Pune University, Pune, Maharashtra, India*

***Received: 3rd Jul, 2025; Revised: 28th Aug, 2025; Accepted: 3rd Sep, 2025; Available Online: 25th Sep, 2025***

**ABSTRACT**

The treatment of cancer has changed significantly as a result of the development of targeted medications, particularly inhibitors of the receptor for epidermal growth factor (EGFR), which is crucial for the development and survival of cancer. Cancers of the colorectal, head and neck, and non-small cell lung varieties often include EGFR overexpression and mutations. The safety records, clinical effectiveness, and action mechanisms of 4thgeneration EGFR inhibitors are the primary foci of this review. The T790M mutation is one example of a resistance mechanism that these newer, more potent inhibitors aim to counteract. In order to give patients with EGFR-mutant cancers that are resistant to earlier treatments new hope, the review outlines recent clinical developments and examines the potential applications of 4th-generation EGFR inhibitors in cancer treatment.

**Keywords:** EGFR inhibitors, T790M mutation, targeted therapy, cancer therapy, clinical efficacy, tumor growth

**How to cite this article:** Asha Hole, Shashikant Bhandari. Advances in Cancer Therapy: A Comprehensive Review of Fourth Generation EGFR Inhibitors and their Role in Defeating Drug Resistance. International Journal of Drug Delivery Technology. 2025;15(3):1406-16. doi: 10.25258/ijddt.15.3.64

**Source of support:** Nil.

**Conflict of interest:** None

## INTRODUCTION

The hallmark of cancer, a multifaceted and intricate disease, is unchecked cell development. In 2020 alone, 19.3 million new cases and approximately 10 million fatalities were reported due to cancer, highlighting the ongoing worldwide health crisis[1]. The creation of tailored therapies is a direct result of the demand for more efficient treatment procedures. Certain molecular changes that occur within tumor cells are the target of these therapies[2]. An important component of cell signaling pathways that control proliferation, differentiation, and survival, the discovery of inhibitors that target EGFR has been a major step forward in targeted cancer treatment[3].

Members of the tyrosine kinase receptor family include the transmembrane glycoprotein EGFR[4]. It becomes active when it attaches to its ligands, starting a cascade of subsequent signaling events that promote cellular processes essential to tumor growth and survival[5]. A number of cancers are frequently linked to aberrant EGFR signaling, most notably cancer of the colon, and cancers of the head and neck, where the carcinogenesis is aided by alterations or overexpression of the receptor[6,7].

The introduction of EGFR inhibitors has progressed through multiple generations, starting with first-generation reversible inhibitors and evolving to third-generation inhibitors specifically designed to overcome resistance mechanisms, particularly the T790M mutation[8]. EGFR inhibitors signifies a major step forward in targeted therapy, providing new hope for patients with advanced EGFR-mutant cancers, especially those resistant to earlier treatments[9].

This review aims to present an inclusive overview of 4th-generation EGFR inhibitors, focusing on mechanisms of action, proven efficiency, safety profiles, and future directions in cancer treatment.

*Understanding EGFR and its Significance in Cancer*

EGFR is engaged in many physiological processes and is essential in cell signaling[10]. It is triggered by the interaction of ligands, which causes autophosphorylation, receptor dimerization, and activation of subsequent signaling ways like PI3K/AKT and RAS/RAF/MEK/ERK.[11] The control of division of cells, survival, and apoptosis depends on these pathways.[12]

*Key Mutations Associated with EGFR in Cancer*

*Exon 19 Deletions*

Commonly observed in NSCLC, leading to constitutive activation of EGFR.[13]

*L858R Point Mutation*

Another prevalent mutation in NSCLC that convenes sensitivity to first- and second-generation inhibitors.[14]

*T790M Mutation*

A secondary mutation that develops in reply to therapy, rendering first- and second-generation inhibitors ineffective.[15]

Targeted therapy development has been accelerated by the identification of certain mutations. In those by activating mutations, first-generation EGFR inhibitors like gefitinib and erlotinib first demonstrated effectiveness[16]. But emergence of resistance precisely, T790M mutation made development of stronger inhibitors necessary.[17] Improved clinical results are possible with third-generation inhibitors

**Author for Correspondence: ashahole21@gmail.com*

Table 1: Recent patented work on 4th generation EGFR inhibitors

| Patent ID | Title | Abstract Summary | Ref. |
|---|---|---|---|
| JP-2022538228-A | Novel macrocycles and derivatives as EGFR inhibitors | The invention relates to compounds used as inhibitors of mutated EGFR, particularly for treating or preventing neoplastic diseases. It includes pharmaceutical compositions and their medicinal uses. | 20 |
| CN-111741954-B | Novel benzimidazole compounds as EGFR inhibitors | This invention describes compounds that act as inhibitors of mutant EGFR, with applications in pharmaceuticals, especially for the treatment or prevention of tumor diseases. | 21 |
| WO-2018108064-A1 | Spiro-aryl-phosphorus-oxygen compound for EGFR kinase | Describes a 4th-generation EGFR kinase inhibitor targeting T790M/C797S mutations, specifically a spiro-aryl-phosphorus-oxygen compound for cancer treatment. | 22 |
| CN-115368378-A | Substituted macrocyclic compounds | The invention covers substituted macrocyclic compounds, useful as 4th-generation non-covalent EGFR tyrosine kinase inhibitors. These compounds inhibit complex EGFR mutations while maintaining selectivity and favorable DMPK properties. | 23 |
| JP-2023550591-A | Substituted 1H-pyrazolo[4,3-c] derivatives | Provides a compound as an inhibitor of mutant EGFR, useful in pharmaceutical compositions for treating or preventing oncological diseases. | 24 |
| KR-20220140534-A | Combination of EGFR inhibitors and ROR1 inhibitors | Describes methods of treating cancer using a combination of a ROR1 antagonist (such as sirumtuzumab) and an EGFR inhibitor (such as osimertinib), with a focus on treating lung cancer, including non-small cell lung cancer. | 25 |
| WO-2020088390-A1 | Pyrimidopyrazole compounds as 4th-generation EGFR inhibitors | Discloses pyrimidopyrazole compounds as 4th-generation EGFR inhibitors, with efficacy against mutations like EGFR Del19/T790M/C797S and L858R/T790M/C797S, for treating diseases caused by abnormal EGFR mutations. | 26 |
| US-11286261-B2 | 4th-generation EGFR tyrosine kinase inhibitor | Describes a compound that specifically inhibits C797S resistant mutant EGFR, used for treating non-small cell lung cancer resistant to previous treatments. | 27 |
| WO-2022265950-A1 | EGFR inhibitor and PERK activator for treating cancer | Provides combinations of EGFR inhibitors and PERK activators for treating cancer, with methods for administering effective doses of these combinations to subjects. | 28 |

like osimertinib, which were created especially to target cancers that were T790M-positive.[18]

*Expansion of 4th Generation EGFR Inhibitors*

4thgeneration EGFR inhibitors have been developed Two-Decade are illustrated in figure 1 to overcome the limitations of previous generations by targeting a broader range of mutations and mechanisms of resistance.[19] These agents are characterized by their irreversible binding to EGFR tyrosine kinase domain, which inhibits downstream signaling pathways more effectively (Table 1).

*Examples of 4th Generation EGFR Inhibitors*

*Osimertinib (AZD9291)*

Official for treating T790M-positive NSCLC, it shows significant action against both primary and acquired mutations.[29]

*Mobocertinib (TAK788)*

A novel oral EGFR inhibitor that has revealed promise in early-phase trials, particularly for patients with difficult-to-treat mutations.[30]

*Other Investigational Compounds*

Several novel agents are currently under clinical investigation, aimed at expanding the treatment options for EGFR-mutant cancers.[31]

The unique characteristics of these 4th-generation inhibitors, including improved selectivity for mutated EGFR and the ability to inhibit multiple resistant mutants, make them highly effective in clinical settings.[32] Their development has been driven by a growing perceptive of the molecular site of tumor and the need for personalized treatment strategies.

*Efficacy of 4th Generation EGFR Inhibitors in Clinical Trials*

The clinical effectiveness of these inhibitors has been demonstrated in various trials summarized in table 2. For example, osimertinib has been evaluated in pivotal trials, including the FLAURA trial, which provided robust evidence of its effectiveness.[38,39]

The FLAURA trial yielded results that compared osimertinib to typical EGFR inhibitors, as gefitinib or erlotinib, using a phase III trial design.[40]

Result: When compared to the 10.2 months observed with standard therapies, the mean progression-free survival (PFS) of patients treated with osimertinib was an impressive 18.9 months.[41]

Furthermore, mobocertinib has demonstrated encouraging outcomes in early-phase clinical trials. Patients by advanced NSCLC who carried EGFR mutations exhibited encouraging response rates in a Phase I/II trial, suggestive of that this medicine may be valuable for patients who are not responding to current treatments.[42]

*4th-Generation EGFR Inhibitors are more Effective and Selective*

Table 2: Summary of Key Clinical Trials for 4th Generation EGFR Inhibitors

| Trial Name | Inhibitor | Study Phase | Patient Population | Outcome | Ref. |
|---|---|---|---|---|---|
| FLAURA | Osimertinib | Phase III | NSCLC with EGFR mutations | PFS: 18.9 months | 33 |
| AURA3 | Osimertinib | Phase III | T790M-positive NSCLC | ORR: 71% | 34 |
| EXCLAIM | Mobocertinib | Phase I/II | Advanced NSCLC | ORR: 42% | 35 |
| PROPHESY | Osimertinib | Phase III | Previously treated NSCLC | Improved OS vs. standard therapy | 36 |
| TATTON | Osimertinib | Phase Ib | Combination with immunotherapy | Enhanced efficacy | 37 |

In order to overcome resistance mechanisms that limited the effectiveness of previous generations, 4th-generation EGFR inhibitors have been developed to specifically target mutations in EGFR that drive the progression of cancer. These inhibitors are more selective and effective in treating EGFR-mutant cancers because of a number of important features.[43]

*Targeting the T790M Resistance Mutation*

Gaining resistance to erlotinib and gefitinib, two EGFR inhibitors from the first and second generations, is frequent, however fourth-generation EGFR drugs can effectively target the T790M resistant mutation. The ATP-binding pocket of EGFR is changed by the T790M mutation, which diminishes the binding affinity of prior inhibitors while keeping ATP binding for tumor cell survival.

To target this mutant form of EGFR and selectively block its activity without affecting wild-type EGFR, researchers developed 4thgeneration inhibitors like osimertinib. This specific targeting confirms that the tumor cells are efficiently inhibited, while normal cells by wild-type EGFR are spared, reducing off-target effects and toxicity.[44]

*Overcoming C797S Mutation*

One major problem is C797S mutation, which interferes with covalent binding of third-generation inhibitors as osimertinib. In order to overcome this resistance, 4th-generation inhibitors are designed to either completely avoid covalent binding or use allosteric mechanisms that circumvent the binding-site changes brought on by the C797S mutation. Because of this, patients who develop resistance following osimertinib therapy benefit from treatment with 4th-generation EGFR inhibitors.[45]

*Increased Selectivity and Lower Toxicity*

The ability of 4th-generation inhibitors to differentiate between mutated and wild-type EGFR results in improved selectivity, which lessens side effects. In normal tissues, previous generations frequently inhibited wild-type EGFR, ensuing in dose-limiting toxicities like diarrhea and skin rash. In contrast, 4th-generation inhibitors have been precisely engineered to bind to the mutant EGFR forms that are common in cancer cells, increasing the therapeutic index and enabling higher effective doses with fewer adverse effects.[46]

*Efficacy in Central Nervous System (CNS) Metastases*

It is typical for individuals with EGFR-mutant NSCLC to develop metastases to the CNS, yet several 4th-generation EGFR inhibitors may also cross the BBB, making them a better treatment option for these patients. One important alternative for patients with advanced cancer is osimertinib, which has shown better efficacy in treating brain metastases than earlier-generation inhibitors.[47]

*Advantages in Overcoming Resistance*

4th-generation EGFR inhibitors not only inhibit the primary activating EGFR mutations but also address resistance mechanisms, especially those that emerge during or after treatment with earlier-generation inhibitors. Here are some of the reasons why they are superior in overcoming resistance:

*Dual Targeting of EGFR Mutations*

4th-generation inhibitors have been designed to target together primary activating EGFR mutations and 2nd resistance mutations (such as T790M and C797S) concurrently. This dual-targeting ability helps to delay or prevent appearance of resistance, encompassing duration of real treatment for patients.[48]

*Combination Therapies*

4th-generation EGFR inhibitors are frequently combined with other agents, such as MET inhibitors or anti-HER2 therapies, to address alternative signaling pathways that tumors may exploit to bypass EGFR inhibition. For example, MET amplification and HER2 overexpression are known resistance mechanisms that can activate bypass pathways to sustain tumor growth. Combining 4th-gen




Figure 1: Two-Decade Overview of EGFR TKI Advancements

Table 3: Common Adverse effects of 4th Generation EGFR Inhibitors

| Adverse Effect | Management Strategies | Comparison with Previous Generations | Clinical Relevance |
|---|---|---|---|
| Rash | Topical steroids, antihistamines | Lower incidence than gefitinib (50%) | Important for patient comfort |
| Diarrhea | Loperamide, dietary adjustments | Similar to erlotinib (30-40%) | Can impact hydration and quality of life |
| Dry skin | Emollients | More prevalent than afatinib (18%) | Requires ongoing management |
| Interstitial lung disease | Discontinue therapy | Higher incidence in earlier generations | Serious but rare complication |
| Fatigue | Supportive care | Comparable to standard therapy | Affects daily activities |
| Nausea | Antiemetics | Similar to first-generation inhibitors | Can lead to treatment discontinuation |
| Elevated liver enzymes | Monitor liver function | Lower incidence than afatinib (20%) | Important for safety monitoring |

Table 4: Resistance Mechanisms to 4th Generation EGFR Inhibitors

| Resistance Mechanism | Description | Impact on Treatment | Possible Solutions | Research Focus | Ref |
|---|---|---|---|---|---|
| C797S mutation | Alters binding site for osimertinib | Reduced efficacy of osimertinib | Development of next-generation inhibitors | Characterization of mutation frequency | 54 |
| MET amplification | Activation of alternative growth pathways | Tumor escape from EGFR inhibition | MET inhibitors in combination therapy | Evaluation of MET-targeting drugs | 55 |
| HER2 overexpression | Compensatory pathway for EGFR signaling | Resistance to EGFR inhibitors | HER2 inhibitors alongside EGFR inhibitors | Dual targeting strategies | 56 |
| KRAS mutations | Activation of downstream signaling independent of EGFR | Poor prognosis | Combination with MEK inhibitors | Understanding KRAS-driven tumors | 57 |
| BRAF mutations | Activation of MAPK pathway | Reduced efficacy of treatment | BRAF inhibitors in combination therapy | BRAF mutation prevalence studies | 58 |
| PD-L1 expression | Immune evasion through upregulation of checkpoint | Resistance to immune therapies | Combining with immunotherapies | Immune profiling in EGFR-mutant tumors | 59 |
| Epithelial-to-mesenchymal transition (EMT) | Phenotypic changes leading to invasiveness | Decreased response to targeted therapy | Investigating EMT inhibitors | Role of EMT in treatment resistance | 60 |

EGFR inhibitors with therapies targeting these parallel pathways can help incredulous resistance and expand outcomes.[49]

*Potential for Biomarker-driven Therapies*

Development of 4th-generation EGFR inhibitors is closely tied to the rise of precision medicine, where specific tumor characteristics guide treatment decisions. By using biomarkers such as the presence of T790M or C797S mutations, clinicians can select patients who are maximum likely to advantage from 4th-generation inhibitors. This personalized approach not only increases efficacy but also helps minimize unnecessary exposure to ineffective treatments, reducing the likelihood of resistance development[50].

*Safety and Tolerability of 4th Generation EGFR Inhibitors*

Security profile of inhibitors is paramount in determining their clinical applicability. Common adverse effects summarized in table 3 associated with these agents often include dermatological reactions, gastrointestinal disturbances, and pulmonary complications.[51]

*Osimertinib Safety Profile*

Table 3 gives a summary of the common adverse effects associated with 4th-generation EGFR inhibitors.[52] These include rash (42%), diarrhea (32%), dry skin (23%), and ILD in almost 2.6% of patients. In comparison with the earlier-generation inhibitors, agents such as osimertinib actually have a manageable safety profile. Thus, most of the adverse actions tend to be mild to moderate and reversible. This tolerability is a key cause in bettering the patient's quality of life and further guaranteeing adherence to treatment schedules[53].

*Current Challenges and Future Perspectives*

Despite the significant advancements provided by 4$^{th}$-generation EGFR inhibitors, several challenges persist. One of utmost important concerns is the emergence of novel resistance mechanisms summarized in detail in table 4. Resistance can occur all the way through various pathways, including mutations in EGFR gene, commencement of another signaling pathways, or phenotypic changes in the tumor cells.

*Resistance Mechanisms*

*Mechanism of Resistance Development*

Not with standing effectiveness of 4th-generation EGFR inhibitors, some resistance mechanisms have arisen, conceding their long-term therapeutic success. Considerate

Table 5: Examples of Combination Therapies

| Aspect | Details | Examples of Combination Therapies | Ref. |
|---|---|---|---|
| Mechanism of Resistance | C797S mutation, which causes resistance to 3rd-generation EGFR-TKIs (e.g., osimertinib). | Combining EGFR-TKIs with monoclonal antibodies or other cytotoxic drugs. | 70 |
| Mutation Impact | C797S mutation disrupts covalent bonding at the ATP binding site, making 3rd-generation inhibitors ineffective. | Osimertinib combined with ramucirumab (anti-angiogenesis agent). | 71 |
| 4th-Generation EGFR TKIs | Designed as allosteric inhibitors targeting sites other than the ATP-binding pocket to overcome C797S mutation resistance. | EGFR-TKIs combined with cytotoxic chemotherapy or radiotherapy. | 72 |
| Key 4th-Gen Inhibitors | EAI001 and EAI045—non-ATP competitive allosteric kinase inhibitors effective against C797S mutation. | EGFR inhibitors combined with cetuximab (EGFR antibody). | 73 |
| Combination Therapy | Combining EGFR-TKIs with other therapies or multi-targeting drugs to enhance anti-tumor efficacy and prevent resistance. | Osimertinib combined with chemotherapeutics or immunotherapy. | 74 |
| Challenges | Development of inhibitors that selectively target the triple mutation (Del19/T790M/C797S). | Targeting multiple signaling pathways to overcome resistance. | 75 |
| Future Strategies | High-throughput screening for lead compounds, including Y-shaped allosteric inhibitors, multi-target agents, and combination therapies. | Combination with drugs targeting angiogenesis or cell death pathways. | 76 |
| Clinical Outcome Focus | Developing inhibitors that offer fewer side effects and higher selectivity for mutant EGFR, leading to better patient outcomes. | Combining EGFR inhibitors with emerging therapies for resistance. | 77 |

Table 6: Comparison of EGFR Inhibitors across Generations

| Generation | Inhibitors | Mechanism of Action | Resistance Mechanisms | Clinical Efficacy | Ref |
|---|---|---|---|---|---|
| 1st | Gefitinib, Erlotinib | Reversible binding to EGFR | T790M mutation | ORR: ~60% in EGFR-mutant NSCLC | 78 |
| 2nd | Afatinib, Dacomitinib | Irreversible binding, pan-ErbB inhibition | T790M mutation | Improved PFS compared to 1st gen | 79 |
| 3rd | Osimertinib | Irreversible binding, selective for T790M | C797S mutation | PFS: 18.9 months in FLAURA trial | 80 |
| 4th | Mobocertinib, EGF816 | Irreversible binding, targets multiple mutants | Emerging resistance mechanisms | Ongoing clinical trials | 81 |

Table 7: Current and Future Directions in EGFR Inhibitor Research

| Research Focus | Objective | Current Status | Potential Impact | Key Challenges | Ref |
|---|---|---|---|---|---|
| Combination Therapies | Enhance efficacy against resistant tumors | Trials ongoing with MET, HER2 inhibitors | Improved patient outcomes | Identifying optimal combinations | 82-84 |
| Biomarker Development | Predictive markers for treatment response | Ongoing studies | Personalized treatment approaches | Variability in mutation detection | 85 |
| Next-Generation Inhibitors | Targeting novel mutations and pathways | Preclinical and clinical trials | Broader efficacy for more patients | Resistance emergence | 86,87 |
| Immunotherapy Combinations | Assess synergistic effects with immune checkpoint inhibitors | Early-phase trials | Enhanced antitumor responses | Balancing immune activation | 88,89 |
| Understanding Resistance | Investigate mechanisms leading to therapy failure | Ongoing research | Informing new treatment strategies | Complexity of resistance mechanisms | 90-93 |

these mechanisms is critical for developing policies to overwhelmed resistance and improve patient outcomes.

*C797S Mutation*

Resistance can manifest in many ways, but one of the most prevalent is the EGFR gene mutation C797S. This mutation changes the binding site of the EGFR inhibitors, especially osimertinib, which makes it less effective at binding and reduces their effectiveness[61]. As a result, tumor cells continue to proliferate despite treatment, leading to disease progression.[62,63]

*MET Amplification*

Another significant mechanism involves the amplification of the MET gene, which activates alternative signaling pathways for tumor growth. MET amplification bypasses the inhibition of EGFR signaling, leading to sustained tumor cell survival and proliferation. This is particularly

problematic in patients who have developed resistance to EGFR-targeted therapies.[64, 65]

*HER2 Over Expression*

In some cases, overexpression of the HER2 receptor compensates for the inhibition of EGFR signaling. HER2 is part of the same receptor family as EGFR and can activate similar downstream signaling pathways. When EGFR is inhibited, HER2 overexpression enables the tumor cells to continue growing, contributing to resistance against EGFR inhibitors.[66]

*Strategies to Overcome Resistance*

To address these resistance mechanisms, combination therapies are being explored. For example, EGFR inhibitors may work in concert with MET inhibitors[67] or immunotherapies[68] to overcome resistance. Furthermore, tailored, biomarker-driven methods that pinpoint particular mutations or patient traits that forecast a reaction to 4th-generation EGFR inhibitors have the potential to improve treatment plans[69]. These strategies seek to reduce side effects while increasing therapeutic efficacy. Constant research goals to explain mechanisms of resistance and create combination treatments that improve the effectiveness of 4$^{th}$-generation inhibitors in order to address these issues. For example, EGFR inhibitors may work in concert with immunotherapies or MET inhibitors to enhance patient outcomes. Additionally, biomarker-driven therapy holds great promise for optimizing treatment strategies. Identifying specific mutations or patient characteristics that predict response to 4$^{th}$-generation inhibitors can lead to more personalized treatment approaches, maximizing therapeutic benefits while minimizing adverse effects. Current and future directions in EGFR inhibitor research is shown in table 5.

*Pharmacophores Explored for Selectivity towards Mutated EGFR*

4$^{th}$-generation EGFR TKIs, like allosteric kinase inhibitors, provide a corresponding method to ATP-competitive inhibitors owing to their different binding sites shown in figure 2. High-throughput screening identified EAI001, a prototype allosteric EGFR TKI, by potent activity against mutant EGFR (L858R/T790M), leading to further development of EAI045. EAI045, while effective in reducing EGFR auto-phosphorylation, did not fully inhibit it due to its selective inhibition of the mutant receptor's activator subunit, which limits its clinical efficacy. Despite this, the modification strategies used in developing EAI045 provide valuable insights for future allosteric inhibitor design aimed at overcoming resistance mutations like T790M/C797S.




Figure 2: Pharmacophore for EGFR

Table 5 provides an overview of strategies to overcome C797S mutation-induced resistance to 3$^{rd}$-generation EGFR-TKIs, highlighting design of allosteric inhibitors, combination therapies, and future directions, including multi-targeting approaches to enhance efficacy and selectivity while reducing side effects.

*Comparison of EGFR Inhibitors*

Comparison of EGFR Inhibitors across Generations also summarized in table 6.

The table 7 outlines ongoing research in EGFR inhibitor development, focusing on combination therapies, biomarker discovery, next-generation inhibitors, immunotherapy combinations, and understanding resistance mechanisms, with the goal of improving efficacy, personalization, and overcoming treatment challenges.

## CONCLUSION

4$^{th}$-generation EGFR inhibitors signify a transformative method in management of EGFR-mutant cancers. Their development has been determined by requirement to address restrictions of earlier therapies and to offer effective options for patients by advanced disease. With their unique mechanisms of action, significant clinical efficacy, and improved safety profiles, these inhibitors have become essential components of modern oncology.

Continued research is vital to fully comprehend complexities of resistance mechanisms and to develop innovative combination therapies that may enhance the overall effectiveness of treatment regimens. As our understanding of cancer biology evolves, so too will the potential applications of 4$^{th}$-generation EGFR inhibitors, ultimately leading to improved patient outcomes and a brighter future for cancer treatment.

## REFERENCES

1. Sobti RC, Thakur M, Kaur T. Cancer: Epidemiology, racial, and geographical disparities. In: Molecular biomarkers for cancer diagnosis and therapy. Edited by: RC Sobti, H Sugimura & A Sobti. 2024 Jun 30;(pp. 31-52). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-3746-2_3
2. Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduction and Targeted Therapy. 2021 May 31;6(1):1-4. https://doi.org/10.1038/s41392-021-00572-w
3. Alharbi KS, Shaikh MAJ, Afzal O, Altamimi AS, Almalki WH, Alzarea SI, Kazmi I, Al-Abbasi FA, Sinek SH, Dua K, Gupta G. An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy. Chemico-Biological Interactions. 2022 Oct 1;366:110108. https://doi.org/10.1016/j.cbi.2022.110108

4. Amelia T, Kartasasmita RE, Ohwada T, Tjahjono DH. Structural insight and development of EGFR tyrosine kinase inhibitors. Molecules. 2022 Jan 26;27(3):819. https://doi.org/10.3390/molecules27030819
5. Ramani S, Samant S, Manohar SM. The story of EGFR: from signaling pathways to a potent anticancer target. Future Medicinal Chemistry. 2022 Sep 1;14(17):1267-88. https://doi.org/10.4155/fmc-2021-0343
6. Uribe ML, Marrocco I, Yarden Y. EGFR in cancer: signaling mechanisms, drugs, and acquired resistance. Cancers. 2021 Jun 1;13(11):2748. https://doi.org/10.3390/cancers13112748
7. Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Seminars in Cancer Biology. 2022 Oct 1;85:253. https://doi.org/10.1016/j.semcancer.2022.04.002
8. Mansour MA, AboulMagd AM, Abbas SH, Abdel-Rahman HM, Abdel-Aziz M. Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review. RSC Advances. 2023;13(27):18285-93. https://doi.org/10.1039/D3RA02137A
9. Papini F, Sundaresan J, Leonetti A, Tiseo M, Rolfo C, Peters GJ, Giovannetti E. Hype or hope: can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC? Critical Reviews in Oncology/Hematology. 2021 Oct 1;166:103454. https://doi.org/10.1016/j.critrevonc.2021.103454
10. Cheng WL, Feng PH, Lee KY, Chen KY, Sun VL, Van Hiep N, Luo CS, Wu SM. The role of EREG/EGFR pathway in tumor progression. International Journal of Molecular Sciences. 2021 Nov 27;22(23):12828. https://doi.org/10.3390/ijms222312828
11. He Y, Sun MM, Zhang GC, Yang J, Chen KS, Xu WW, Li B. Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduction and Targeted Therapy. 2021 Dec 16;6(1):425. https://doi.org/10.1038/s41392-021-00828-5
12. Wang R. Regulation of cell cycle progression by growth factor-induced cell signaling. Cells. 2021 Nov 26;10(12):3327. https://doi.org/10.3390/cells10123327
13. Brown BP, Zhang YK, Kim S, Finneran P, Yan Y, Du Z, Kim J, Hartzler AL, LeNoue-Newton ML, Smith AW, Meiler J, Lovely CM. Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 2022 Jul 26;119(30):e2200585119. https://doi.org/10.1073/pnas.2200585119
14. Turmbnik HL, Heimsoeth A, Sos ML. The next tier of EGFR resistance mutations in lung cancer. Oncogene. 2021 Jan 7;40(1):1-11. https://doi.org/10.1038/s41388-020-01551-6
15. Dong RF, Zhu ML, Liu XM, Xu YF, Yuan L, Bian J, Xia YZ, Kong LY. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: revealing molecular mechanism to clinical research. Pharmacological Research. 2021 May 1;167:105583. https://doi.org/10.1016/j.phrs.2021.105583
16. Wu Q, Luo W, Li W, Wang T, Huang L, Xu F. First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutations: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Oncology. 2021 Apr 12;11:635546. https://doi.org/10.3389/fonc.2021.635546
17. Shi K, Wang P, Shi J, Zhang J, Wang J, Duynant L, Wang Y, Li W. Emerging strategies to overcome resistance to third-generation EGFR-TKIs in advanced NSCLC. Journal of Hematology & Oncology. 2022 Jul 15;15(1):94. https://doi.org/10.1186/s13045-022-01341-5
18. Nagasaka M, Zhu VW, Lim SM, Greco M, Wu F, Ou SI. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced NSCLC. Journal of Thoracic Oncology. 2021 May 1;16(5):740-56. https://doi.org/10.1016/j.jtho.2020.12.015
19. Fukuda S, Suda K, Hamada A, Oiki H, Ohara S, Ito M, Soh J, Mitsudomi T, Tsutani Y. Potential utility of a 4th-generation EGFR-TKI and exploration of resistance mechanisms—an in vitro study. Biomedicines. 2024 Jun 21;12(7):1412. https://doi.org/10.3390/biomedicines12071412
20. JP-2023532928-A. Novel macrocycles and derivatives as EGFR inhibitors. BoehringerIngelheim International GmbH. Published on Sep 14 2023. Available from: https://patents.google.com/patent/JP2023532928A/en
21. CN-111474958-A. Novel imidazole compounds and derivatives as EGFR inhibitors. BoehringerIngelheim International GmbH. Published on Jul 31 2020. Available from: https://patents.google.com/patent/CN111474958A/en
22. WO-2018165014-A1. Spiro-pyridyl-phosphorus-oxygen compound as fourth generation EGFR kinase inhibitor. Nanjing Medchem Pharmaceutical Co., Ltd. Published on Sep 13 2018. Available from: https://patents.google.com/patent/WO2018165014A1/en
23. CN-113968734-A. Substituted macrocyclic compounds, compositions containing the same and uses thereof. Shenzhen Taishirui Biopharmaceutical Co., Ltd. Published on Jan 25 2022. Available from: https://patents.google.com/patent/CN113968734A/en
24. US-20230275514-A1. Substituted 1H-pyrrolo. BoehringerIngelheim International GmbH. Published on Aug 24 2023. Available from: https://patents.google.com/patent/US20230275514A1/en
25. KR-20220014034-A. Combination of EGFR inhibitors and ROR1 inhibitors for the treatment of cancer. Onctherapy Science, Inc. Published on Feb 11 2022. Available from: https://patents.google.com/patent/KR20220014034A/en

26. WO-2021008850-A1. Pyrimidopyrazol compounds as fourth generation EGFR inhibitors. Jiangsu Hengrui Medicine Co., Ltd. Published on May 7 2020. Available from: https://patents.google.com/patent/WO2021008850A1/en
27. US-11286268-B2. Fourth-generation EGFR tyrosine kinase inhibitor. Nagasaki University, Iwate Medical University, Japanese Foundation for Cancer Research. Published on Mar 29 2022. Available from: https://patents.google.com/patent/US11286268B2/en
28. WO-2022252594-A1. EGFR inhibitor and PERK activator in combination therapy and their use for treating cancer. Qventus Life Sciences Pvt Ltd. Published on Dec 1 2022. Available from: https://patents.google.com/patent/WO2022252594A1/en
29. Remon J, Besse B, Aix SP, Cejalvo A, Al-Naqib R, Bernabé R, Greillier L, Majem M, Reguart N, Monnet I, Cousin S, Camara P, Robinet G, Garcia Campelo R, Mazières J, Audigier-Valette C, Moro-Sibilot D, Westeel V, Baize N, Pérol M, Brosseau S, Zalcman G, Jovelet C, Girard N, Pannet C, Hollebecque A, Le Moulec S, Planchard D, Caramella C, de Baere T, Nanni L, Gazzah A, Dingemans AC, Dziadziuszko R. Osimertinib treatment beyond progression in patients (pts) with EGFR exon 20 insertion mutation non-small cell lung cancer (NSCLC): DCR cohort from the Lung Cancer Group Riga 1651 APPLE phase II randomized clinical trial. Annals of Oncology. 2023 Jan 1;34(S1):S1209-38. https://doi.org/10.1016/annonc.2023.02.012
30. Riley GM, Jackson CM, Corridige GR, Spira AI, Piotrowska Z, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Batenchuk C, Lieu JW, West HL, Mekhail T, Gernstner RD, Nguyen D, Vincent S, Zhang S, Lin J, Buon VM, Li S, Jin S, Jänne PA. Activity and safety of mobocertinib (TAK-788) in previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations from a phase I/II trial. Cancer. 2021 Apr 1;127(7):1158-68. https://doi.org/10.1002/cncr.33380
31. Tajane P, Kayande N, Bhosale A, Deore S, Tare H. Design and discovery of silmitasertib-based drugs as a potential casein kinase II inhibitor for cholangiocarcinomathrough hybrid in-silico ligand-based virtual screening with molecular docking method. *Int J Drug Deliv Technol*. 2023;13(4):1514-9. https://doi.org/10.25258/ijddt.13.4.60
32. He J, Zhou Z, Sun X, Yang Z, Zheng P, Xu S, Zhu W. The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors in overcoming C797S mutation. European Journal of Medicinal Chemistry. 2021 Jan 15;210:113995. https://doi.org/10.1016/j.ejmech.2020.113995
33. Ohe Y, Imamura S, Nogami N, Okamoto I, Kurata T, Kato T, Sugawara S, Ramalingam SS, Goto K, Hodge R, Vowler SL, Wajima T, Nishiwaki A, Nakagawa K. Osimertinib versus gefitinib as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Japanese Journal of Clinical Oncology. 2019 Jan;49(1):29-36. https://doi.org/10.1093/jjco/hyy158
34. Papadimitrakopoulou VA, Han JY, Ahn MJ, Ramalingam SS, Delmonte A, Hsia TC, Laskin J, Kim SW, He Y, Tsai CM, Yang JC, Ohe Y, Kato T, Jenkins S, Patel S, Huang X, Lu S, Gruslova A, Threats KS, Wu YL, Mai H. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer. 2020 Jan 15;126(2):373-380. https://doi.org/10.1002/cncr.32508
35. Hanley MJ, Camidge DR, Fram RJ, Gupta N. Mobocertinib: Mechanism of action, clinical, and translational science. Clinical and Translational Science. 2024 Mar;17(3):e13766. https://doi.org/10.1111/cts.13766
36. Markou A, Tzanikou E, Lianidou E. The potentials of liquid biopsy in the management of cancer patients. Annals of Translational Medicine. 2020 Aug;8(16):1089. https://doi.org/10.21037/atm.2020.03.194
37. Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. *Ann Oncol*. 2020;31(4):507-16. https://doi.org/10.1016/j.annonc.2020.01.013
38. Lamb YN. Osimertinib: a review in previously untreated EGFR mutation-positive advanced NSCLC. Target Oncol. 2021;16(5):687-95. https://doi.org/10.1007/s11523-021-00839-w
39. Viray H, Piper-Vallillo AJ, Widick P, Academia E, Shea M, Rangachari D, et al. Real-world study of patient characteristics and clinical outcomes in EGFR-mutated lung cancer treated with first-line osimertinib: expanding the FLAURA trial results into routine clinical practice. Cancers (Basel). 2024;16(6):1079. https://doi.org/10.3390/cancers16061079
40. Cheng Y, He Y, Li W, Zhang HL, Zhou Q, Wang B, et al. Osimertinib versus comparator EGFR-TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China. Target Oncol. 2021;16(2):165-76. https://doi.org/10.1007/s11523-021-00794-6
41. Asahina H, Tanaka K, Morita S, Maemondo M, Seike M, Okamoto I, et al. A phase II study of osimertinib combined with platinum plus pemetrexed in patients with EGFR-mutated advanced non–small-cell lung cancer: the OPAL study (NEJ032C/LOGIK1801). Clin Lung Cancer. 2021;22(2):147-51. https://doi.org/10.1016/j.cllc.2020.09.023
42. Arnold A, Ganti AK. Clinical utility of mobocertinib in the treatment of NSCLC—patient selection and reported outcomes. Onco Targets Ther. 2023;16:559-69. https://doi.org/10.2147/OTT.S374489
43. Su C, Sun SY. Fourth-generation epidermal growth factor receptor-tyrosine kinase inhibitors: hope and challenges. Transl Cancer Res. 2024;13(8):3929-36. https://doi.org/10.21037/tcr-24-406

44. Melis JU, Kevenaar K, Kooijman JJ, Grobben Y, Ytsma J, Bertran-Alamillo J, Molina-Vila MA, Willemsen-Seegers N, Zaman GJ. Abstract 4663. Characterization of fourth-generation EGFR inhibitors in binding experiments with C797S mutant EGFR and cell-based assays with osimertinib-resistant non-small cell lung cancer cell lines. Cancer Research. 2024 Mar 22;84(6_Supplement):4663. https://doi.org/10.1158/1538-7445.AM2024-4663
45. Wu T. Research on bioinformatics: Characterizing EGFR-TKIs. Insights in Science, Engineering and Technology. 2023 Dec 22;5(4):175-184. https://doi.org/10.34207/ibseet.2023.54021
46. Zhang X, Liu E, Song Y, Yu P, Rediar S, Yu L. Abstract 6509. Dependence of EGFR-mutant NSCLC on MET as demonstrated by vebreltinib, a novel and selective brain-penetrating MET kinase inhibitor. Cancer Research. 2024 Mar 22;84(6_Supplement):6509. https://doi.org/10.1158/1538-7445.AM2024-6509
47. Yang Y, He X, Xiao W, Bai J, Li Y. Ensartinib is effective in the treatment of advanced non-small cell lung cancer with MET amplification after multiple ALK-TKIs resistance: a case report. Anti-Cancer Drugs. 2024 Mar 1;35(2):252-4. https://doi.org/10.1097/CAD.0000000000001394
48. Scanlon E, Lavery A, Abhrabri M, Stevenson L, Kennedy C, Byrne R, Walker A, Mullan-Young B, McMullan D, Curtis S, Heuson C, Turville I, Collinson D, Midgley R, Davidson N, Schrijver WAME, McGloin S, James TA, Craig SG, Blayney JK, Petty R, Hanlon R, Kennedy RD, Fallow MJW, Middleton M, Hanna G, Tunjiakin A. Neoadjuvantosimertinib with/without chemotherapy for EGFR-mutant lung adenocarcinoma: a translational study of the neoadjuvant cohort. Journal of Thoracic Oncology. 2024 Nov 14:S1556-0864(24)01930. https://doi.org/10.1016/j.jtho.2024.10.006
49. Johnson ML, Girda E, Sohal D, Lakhani NJ, Olszanski AJ, Fong L, Kinnaman M, Han H, Moesta A, Hao Y, Li S, Jänne PA. Phase 1/2 study of REGN7075 (EGFR×CD28) combined with cemiplimab in patients with advanced solid tumors. Journal of Clinical Oncology. 2024 May 20;42(16_suppl):TPS2674. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS2674
50. Lin JJ, Gainor JF. Current opportunities and challenges in ALK-positive lung cancer. Translational Lung Cancer Research. 2024 Jan 22;13(1):1. https://doi.org/10.21037/tlcr-2023-4
51. Bhargava P, Robinson MO. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. *Current Oncology Reports.* 2011 Apr;13(2):103-44. https://doi.org/10.1007/s11912-011-0142-4
52. Xu L, Xu B, Wang J, Song Y, He X, Xia Y, Ye X. Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy. *European Journal of Medicinal Chemistry.* 2021 May;217:113372. https://doi.org/10.1016/j.ejmech.2021.113372
53. Mesquita L, Vargas A, Planchard D. Safety of osimertinib in EGFR-mutated non-small cell lung cancer. *Expert Opinion on Drug Safety.* 2018 Dec 2;17(12):1239-48. https://doi.org/10.1080/14740338.2018.1534289
54. Li Y, Mo S, Wang J, Zheng H, Xu R, Cao P, Yang S, Zhu L, Guo S, Zhao K, Tian Y, Shen H, Lin F. Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer. *Cell Communication and Signaling.* 2023 Dec;21:136. https://doi.org/10.1186/s12964-023-01138-3
55. Rivas S, Marín A, Samtani S, González-Feliú E, Armisén R. MET signaling pathways, resistance mechanisms, and therapeutic opportunities. Int J Mol Sci. 2022;23(22):13898. https://doi.org/10.3390/ijms232213898
56. Yonesaka K. HER2-/HER3-targeting antibody-drug conjugates for treating lung and colorectal cancers resistant to EGFR inhibitors. Cancers. 2021;13(5):1047. https://doi.org/10.3390/cancers13051047
57. Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. *Signal Transduction and Targeted Therapy.* 2021 Nov 15;6(1):386. https://doi.org/10.1038/s41392-021-00788-4
58. Poulikakos PI, Sullivan RJ, Yaeger R. Molecular pathways and mechanisms of BRAF in cancer therapy. *Clinical Cancer Research.* 2022 Nov 15;28(21):4559–72. https://doi.org/10.1158/1078-0432.CCR-21-1148
59. Sienc C, Compes A, Nill M, Borchmann S, Odenthal M, Florin A, Brägelmann J, Büttner R, Meder L, Ullrich RT. EGFR inhibition strongly modulates the tumour immune microenvironment in EGFR-driven non-small-cell lung cancer. *Cancer.* 2022 Aug 15;64(14):1983–99. https://doi.org/10.3390/cancers14181983
60. Garg M. Emerging roles of epithelial–mesenchymal plasticity in invasion–metastasis cascade and therapy resistance. *Cancer and Metastasis Reviews.* 2022 Mar;41(1):43–68. https://doi.org/10.1007/s10555-021-09983-8
61. Lim SM, Cho BC, Han Y, Kim SW, Lee KH, Nagasaka M, Jo A, Seoh K, Kim C, Reungwetwattana T. Phase 1/1b clinical trial of YH25448, a 3rd generation EGFR-TKI, in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced/metastatic non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology.* 2024;42(16_suppl):TPS8568. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS8568
62. Dickerson D, Diogo A, Al M. *Epidermal growth factor receptor (EGFR) in various cancer types: existing inhibitors in the clinic and future approaches.International Journal of Molecular Sciences.* 2024 Sep 17;25(18):10008. https://doi.org/10.3390/ijms251810008
63. Dou D, Zhang X, Wang J, Wumaier G, Qiao Y, Xie L, Jiang W, Sha W, Li W, Mei W, Zhang C, He H, Wang C, Wu L, Diao Y, Zhu L, Zhao Z, Chen Z, Xu Y, Li S, Li H. Design, synthesis, and biological evaluation of

diphenyl ether substituted quinazolin-4-amine derivatives as potent EGFRL858R/T790M/C797S inhibitors. *European Journal of Medicinal Chemistry.* 2024 Dec 5;279:116858. https://doi.org/10.1016/j.ejmech.2024.116858

64. Corvaja C, Passaro A, Attili I, Aldrighetti G, Spitaleri G, Del Signore ÊED, de Marinis F. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: distinguishing biological insights and therapeutic development. *Cancer Treatment Reviews.* 2024 Sep;124:103824. https://doi.org/10.1016/j.ctrv.2024.103824
65. Thomson C, Braybrooke E, Colclough N, Davies NJ, Floch N, Greenwood R, Guérot C, Hargreaves D, Johnstone P, Khurana S, Kotomori HJ. Optimization of Potent, Efficacious, Selective and Blood–Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations. *Journal of Medicinal Chemistry.* 2024 Oct 3. https://doi.org/10.1021/acs.jmedchem.4c01547
66. Dudgeon C, Fujiyama S, Funk O, Tamirefa F, Kangas TO, Zhang W, Lightcap ES, Surguladze D, Bose N. LHSparc-4665/FCN-7366, a potent GCN2 kinase activator, augments osimertinib therapy to delay resistance in EGFR mutant NSCLC models. *Cancer Research.* 2024 Mar 22;84(Suppl_16_Supplement):4665. https://doi.org/10.1158/1538-7445.AM2024-4665
67. Lee E, Oh SY, Lee WN, Kim JY, Kim MJ, Kim TH, Jeong MS, Lim SM, Baum A, Weingberger L, Engelhart H, Petronczki M, So M, Yun M, Cho BC. Discovery of a novel potent EGFR inhibitor against EGFR activating mutations and on-target resistance in NSCLC. *Clinical Cancer Research.* 2024 Apr 19:clincanres.0567.2023. https://doi.org/10.1158/1078-0432.CCR-23-2561
68. Lin JJ, Gainor JF. Current opportunities and challenges in ALK-positive lung cancer. *Translational Lung Cancer Research.* 2024 Jan 1;13(1). https://doi.org/10.21037/tlcr-2023-021
69. Go Y, Yoshieka S, Yoshida N, Yoshimi S, Kouzaiho A, Toya K, Kurumida K, Ogasaw T, Tsuchii T, Yamaguchi F. Prolonged survival in osimertinib-resistant EGFR-mutated adenocarcinoma. *Current Problems in Cancer.* 2024 Oct 18:105392. https://doi.org/10.1016/j.currproblcancer.2024.105392
70. Rocco D, Della Gravara L, Boccia MC, Palaoro G, Gridelli C. Novel combination of anti-angiogenesis in adenocarcinoma NSCLC with EGFR activating mutations. *Targets.* 2024 Sep 7;28(3):237–46. https://doi.org/10.3390/targets20300164
71. Kermost H. Combination of ramucirumab and osimertinib for EGFR-mutated non-small cell lung cancer: Phelps for new beginnings. *Journal of Clinical Oncology.* 2024 Oct 15;20–24. https://doi.org/10.1200/JCO.24.01592
72. Liu LJ, Li H, Chen CY, Li TT, Deng B, Ling Z, Liu J. Efficacy evaluation of targeted therapy in EGFR-mutated advanced lung adenocarcinoma. *Current Problems in Cancer.* 2024 Aug;48(4):100873. https://doi.org/10.1016/j.currproblcancer.2024.100873
73. Nguyen JP, Woerner LC, Johnson DE, Grandis JR. Future investigation directions for novel therapeutic targets in head and neck cancer. *Expert Review of Anticancer Therapy.* 2024 Feb 1;24(2):123–40. https://doi.org/10.1080/14737140.2024.2470872
74. Papavasileiou KA, Sofianid A, Dgoua VA, Papavasileiou AS. The emerging role of angiogenesis in shaping the lung cancer microenvironment. *Cells.* 2024 Oct 18;13(20):1793. https://doi.org/10.3390/cells13201793
75. Guo J, Liu F, Liu X, Fu B, Bais Q, Ren W, Kong D, Xu B, Sun X, Zhang Y, Cai W, Wang D, Chen C, Ren S, Zhou C, Lin J, Ding W, Wang J. BLU-945, a highly potent, CNS-penetrant 4th generation EGFR inhibitor overcoming major EGFR resistance mutations in NSCLC. *Cancer Research.* 2024 Mar 22;84(Suppl_16_Supplement):5514. https://doi.org/10.1158/1538-7445.AM2024-5514
76. Ansari MJ, Bokov D, Markov A, Jalil AT, Shalaby MN, Suksatan W, Chupradit S, Al-Ghamdi HS, Shomali N, Zamani A, Mohammadi A. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. Cell Communication and Signaling. 2022 Apr 7;20(1):49.
77. Aggarwal V, Kim C. J.39 MET point mutations as the mechanism of resistance to EGFR-TKI therapy: A case report of MET H1094Y-mediated resistance to osimertinib overcoming by capmatinib and a systematic review. *Journal of Thoracic Oncology.* 2024 Oct 1;19(10):S637. https://doi.org/10.1016/j.jtho.2024.09.1148 https://doi.org/10.1186/s12964-022-00838-y
78. Kageji H, Momose T, Ebisawa M, Nakazawa Y, Okada H, Togashi N, Nagamoto Y, Obuchi W, Yasumatsu I, Kihara K, Hiramoto K, Minami M, Kasamuki N, Isoyama T, Naito H, Tanaka N. Discovery of a potent, selective, and orally active EGFR C797S mutant inhibitor (D05866293) with in vivo antitumor activity. *Bioorganic & Medicinal Chemistry.* 2024 Sep 1;141:117862. https://doi.org/10.1016/j.bmc.2024.117862
79. Cheng WC, Lin CC, Liao WC, Lin CY, Chen CH, Chen IU, Tu CY, Hsia TC. The difference between combination and bifatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study. *BMC Cancer.* 2022 Feb 19;24(1):228. https://doi.org/10.1186/s12885-024-11956-w
80. Chmielecki J, Gray JE, Cheng Y, Ohe Y, Imamura F, Cho BC, Lin MC, Majem M, Shah R, Rukazenkov Y, Todd A, Markovets A, Barrett JC, Hatamie R, Banalemnis S. osimertinib plus savolitinib versus osimertinib monotherapy in EGFR-mutated advanced non-small cell lung cancer. *Nature Communications.* 2023 Feb 27;14(1):1070. https://doi.org/10.1038/s41467-023-36917-8
81. Tian X, Gu T, Lee MH, Dong Z. Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. *Reviews on Cancer*

*(BiochimicaetBiophysicaActa).* 2022 Jan 1;1877(1):188645. https://doi.org/10.1016/j.bbcan.2021.188645

82. Waks AG, Martínez-Sáez O, Tarantino P, Braso-Maristany F, Pascual T, Cortés J, Tolaney SM, Prat A. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance. *Nature Reviews Clinical Oncology.* 2024 Sep 13;21(11):***8118. https://doi.org/10.1038/s41571-024-00932-9
83. Tapia M, Hernando C, Martínez MT, Burgue s, Tober-Sánchez C, Lameirinhas A, Ágreda-Roca A, Torres-Ruiz S, Garrido-Cano I, Luch A, Bermejo E, Eroles P. Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical anti-HER therapies. *Cancers.* 2023 Sep 12;15(18):4522. https://doi.org/10.3390/cancers15184522
84. Passaro A, Al Banji M, Hamilton EG, Dihen M, André F, Roy-Chowdhuri S, Mountzios G, Wistuba II, Swanton C, Peters S. Cancer biomarkers: emerging concepts and clinical implications for personalised treatment. *Cell.* 2024 Mar 28;187(7):1617-28. https://doi.org/10.1016/j.cell.2024.02.041
85. Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. *Nature Medicine.* 2021 Aug;27(8):1345-56. https://doi.org/10.1038/s41591-021-01450-2
86. Wensink GE, Elias SG, Mullenders J, Koopman M, Bosj E, Kranenburg OW, Doornebal CW. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. *npj Precision Oncology.* 2021 Apr 12;5(1):30. https://doi.org/10.1038/s41698-021-00185-y
87. Marrocco I, Yarden Y. Resistance of lung cancer to EGFR-specific kinase inhibitors: activation of bypass pathways and endogenous mutators. *Cancers (Basel).* 2023;15(20):5009. https://doi.org/10.3390/cancers15205009
88. Sanborn RE, Schnieders FL, Senan S, Gadgeel SM. Beyond checkpoint inhibitors: enhancing antitumor immune response in lung cancer. *American Society of Clinical Oncology Educational Book.American Society of Clinical Oncology Annual Meeting.* 2022 Jun 7;42:e833-45. https://doi.org/10.1200/EDBK_350967
89. Corke L, Sacher A. New strategies and combinations to improve outcomes in Immunotherapy in metastatic non-small-cell lung cancer. *Current Oncology.* 2021 Dec 23;29(1):38-55. https://doi.org/10.3390/curroncol29010004
90. Laface C, Maselli FM, Santoro AN, Isia ML, Ambrogio F, Laterza M, Guarini C, De Santis P, Perrone M, Fedele P. The resistance to EGFR-TKIs in non-small cell lung cancer: from molecular mechanisms to clinical application of new therapeutic strategies. *Pharmaceuticals.* 2023 May 27;15(6):1604. https://doi.org/10.3390/ph15061604
91. Reita D, Pabst L, Pencreach E, Guérin E, Dano L, Rimelen V, Voegeli AC, Vallet J, Mascaux C, Beau-Faller M. Molecular mechanism of EGFR-TKI resistance in EGFR-mutated non-small cell lung cancer: application to biological diagnostic and monitoring. *Cancers.* 2021 Sep 30;13(19):4926. https://doi.org/10.3390/cancers13194926
92. Kobayashi K, Tan AC. Unraveling the impact of intratumoral heterogeneity on EGFR tyrosine kinase inhibitor resistance in EGFR-mutated NSCLC. International Journal of Molecular Sciences. 2023 Feb 18;24(4):4126. https://doi.org/10.3390/ijms24044126
93. Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nature Reviews Cancer. 2022 Jun;22(6):323-48. https://doi.org/10.1038/s41568-022-00454-5